LoginSignup
CYB

Cybin

Stock
Stock
ISIN: CA23256X4075
Ticker: CYBN
CA23256X4075
CYBN

Price

Price

CHART BY

Frequently asked questions

What is Cybin's market capitalization?

The market capitalization of Cybin is $192.06M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Cybin?

Cybin's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$5.662. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Cybin's stock?

Currently, 6 analysts cover Cybin's stock, with a consensus target price of $93.43. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Cybin?

Cybin's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$90.61M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Cybin?

Cybin has a free cash flow of -$69.49M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the free float of Cybin's shares?

The free float of Cybin is 18.44M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$192.06M
EPS (TTM) 
-$5.662
Free Float 
18.44M
EBITDA (TTM) 
-$90.61M
Free Cashflow (TTM) 
-$69.49M

Pricing

1D span
$9.304$10.29
52W span
$0.184$13.81

Analyst Ratings

The price target is $93.43 and the stock is covered by 6 analysts.

Buy

6

Hold

0

Sell

0

Information

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Industries
Pharmaceuticals: Major
Sector
Health Care

Identifier

ISIN
CA23256X4075
Primary Ticker
CYBN

Knockouts

Join the conversation
Sign upLogin